Abstracts tagged "Polymyalgia Rheumatica (PMR)"

Abstract Number: 1565 • ACR Convergence 2023
Baseline Vascular Ultrasound of Polymyalgia Rheumatica Patients at Time of Diagnosis Predicts Clinical Outcomes at 3 Months
Sharon Cowley¹, Colm Kirby², Patricia Harkins³, Richard Conway⁴ and David Kane⁵, ¹Tallaght University Hospital, Dublin, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Ireland, ³St James's Hospital, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland
Background/Purpose: It has been reported that up to a quarter of patients with polymyalgia rheumatica (PMR) have subclinical giant cell arteritis (GCA). It is currently…
Abstract Number: 1566 • ACR Convergence 2023
Exposure-Response Analysis of Sarilumab in Patients with Polymyalgia Rheumatica
Christine Xu¹, Ying Liu¹, Jennifer Sloane², Remco Diab³, Hubert van Hoogstraten¹, Hisham Abdallah⁴, Sreeraj Macha¹ and Bhaskar Dasgupta⁵, ¹Sanofi, Bridgewater, NJ, ²Sanofi, Cambridge, MA, ³Sanofi, Rotkreuz, Switzerland, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Anglia Ruskin University, East Anglia, United Kingdom
Background/Purpose: Sarilumab blocks interleukin-6 (IL-6) from binding to the membrane-bound and soluble IL-6 receptor-α subunit (IL-6Rα). Sarilumab is now approved for both rheumatoid arthritis (RA)…
Abstract Number: 1649 • ACR Convergence 2023
Follow-up Ultrasound Examination in Patients with Newly Diagnosed Giant Cell Arteritis
Lara Clarissa Burg¹, Christian Dejaco², Pantelis Karakostas³, Charlotte Behning⁴, Peter Brossart¹ and Valentin Sebastian Schäfer³, ¹University Hospital of Bonn, Bonn, Germany, ²Department of Rheumatology, Medical University Graz, Graz, Austria; Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy, ³Clinic of Internal Medicine III, Department of Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital of Bonn, Bonn, Germany, ⁴Institute of Medical Biometry, Informatics and Epidemiology, Medical Faculty, University of Bonn, Bonn, Germany
Background/Purpose: In recent years, ultrasound has become a standard tool in the diagnosis of giant cell arteritis (GCA). Typical findings are increased intima media thickness…
Abstract Number: 0027 • ACR Convergence 2023
Association of HLA-DRB1 and ANKRD55/IL6ST Regions with Polymyalgia Rheumatica Diagnosis: A Genome Wide Association Study from UK Biobank and FinnGen
Mehmet Hocaoglu¹, Jamal Mikdashi², James Perry² and Charles Hong², ¹University of Maryland School of Medicine, Pittsburgh, PA, ²University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: The existing literature on the genetics of polymyalgia rheumatica (PMR) is limited to candidate gene studies with small sample sizes. There is a need…
Abstract Number: 1869 • ACR Convergence 2023
FDG-PET/CT for Diagnosing Polymyalgia Rheumatica Before, During and After a Short-term Prednisolone Cessation – a Prospective Study of 101 Patients
Andreas Wiggers Nielsen¹, Ib Tønder Hansen², Berit Dalsgaard Nielsen³, Søren Geill Kjær⁴, Jesper Blegvad-Nissen⁴, Christian Møller Sørensen³, Ellen-Margrethe Hauge¹, Lars Christian Gormsen² and Kresten Krarup Keller¹, ¹Aarhus University Hospital, Aarhus, Denmark, ²Aarhus University Hospital, Aarhus N, Denmark, ³Department of Internal Medicine, Horsens, Denmark, ⁴Diagnostic Centre, Silkeborg, Denmark
Background/Purpose: Polymyalgia rheumatica (PMR) can be challenging to diagnose since other diseases may present with similar symptoms. As a result, a significant number of patients…
Abstract Number: 0267 • ACR Convergence 2023
Variations in Approach to the Diagnosis and Management of Polymyalgia Rheumatica Among Australian Rheumatologists
Victor Yang¹, Jem Ninan², David Liew¹, Helen Keen³, Catherine Hill⁴ and Jessica Leung⁵, ¹Austin Health, Heidelberg, Australia, ²University of Adelaide, Adelaide, Australia, ³University of Western Australia, Daglish, Australia, ⁴The Queen Elizabeth Hospital, Woodville, Australia, ⁵Austin Health, Preston, Australia
Background/Purpose: Polymyalgia rheumatica (PMR) is the second-most common inflammatory rheumatic disease but there remains variation amongst rheumatologists in approaches to diagnosis and management. This study…
Abstract Number: 1878 • ACR Convergence 2023
MRI-determined Intramuscular Fat Changes During Oral Glucocorticoid Treatment: Findings from a Feasibility Study
Thurkka Rajeswaran¹, Emma Harris², hannah Mathieson¹, John Biglands³, Paul Stewart¹, Ai Lyn Tan¹ and Sarah Mackie⁴, ¹University of Leeds, Leeds, United Kingdom, ²The Open University, Milton Keynes, United Kingdom, ³NIHR Leeds Biomedical Research Centre and Medical Physics and Engineering , Leeds Teaching Hospitals NHS Trust Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Oral glucocorticoid therapy has many adverse effects including insulin resistance and myopathy. Long-term glucocorticoid therapy causes a "sarcopenic obesity" phenotype of adiposity with muscle…
Abstract Number: 0717 • ACR Convergence 2023
Mitochondria-mediated Platelet Activation in Polymyalgia Rheumatica
Despoina Michailidou¹, Linda Johansson², Jorge Armando Gonzalez-Chapa¹, Ting Wang¹, Junmei Chen³, José A. López³, Solbritt Rantapää-Dahlqvist⁴ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Umea University, Umea, Sweden, ³Bloodworks Research Institute, Seattle, WA, ⁴Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden
Background/Purpose: Platelets have been suggested to be involved in polymyalgia rheumatica (PMR) pathogenesis with elevated platelet activation observed in early stages of the disease. Upon…
Abstract Number: 1890 • ACR Convergence 2023
Use of Artificial Intelligence to Diagnose Polymyalgia Rheumatica on 18F-FDG Whole Body PET/CT in Patients with Atypical Clinical Features
Emily Martin¹, Christopher McMaster¹, Saskia Rowson¹, Victor Yang¹, Aurora Poon¹, Bonnia Liu¹, Jessica Leung², Andrew Scott¹, David Liew¹ and Claire Owen³, ¹Austin Health, Heidelberg, Australia, ²Austin Health, Preston, Australia, ³Austin Health, Malvern East, Australia
Background/Purpose: PET/CT is a highly sensitive and specific test for diagnosing PMR.(1) This study investigated the utility of 18F-FDG whole body PET/CT in patients presenting…
Abstract Number: 0718 • ACR Convergence 2023
Clinical and Economic Burden of Polymyalgia Rheumatica in Patients with an Inadequate Response to Glucocorticoids in a Real-World Setting
Jeffrey Curtis¹, Lita Araujo², Stefano Fiore², Sebastian Sattui³, John Stone⁴, Kerri Ford² and Fenglong Xie⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Sanofi, Cambridge, MA, ³University of Pittsburgh, Pittsburgh, PA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, ⁵Illumination Health, Hoover, AL
Background/Purpose: The burden of continuing glucocorticoids (GCs) in patients with polymyalgia rheumatica (PMR) who have an inadequate response (IR)to GCs has not been evaluated.Methods: An…
Abstract Number: 2392 • ACR Convergence 2023
Characterization of Arterial Dendritic Cells in Polymyalgia Rheumatica and Giant Cell Arteritis
andre ramon¹, helene Greigert², corentin Richard³, claudie cladière⁴, coraline genet⁵, marion ciudad⁶, georges tarris⁷, laurent martin⁸, louis arnould⁹, catherine creuzot-garcher¹⁰, paul ornetti¹¹, Sylvain Audia¹², romain boidot³, jean-Francis Maillefert¹¹, Bernard Bonnotte² and Maxime Samson², ¹Department of Rheumatology, Dijon University Hospital, Dijon, France, ²Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ³Département de Biologie et de Pathologie des Tumeurs, ICMUB UMR CNRS 6302, Centre Georges François Leclerc, Dijon, France, ⁴INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Bourgogne Franche-Comté University, Dijon, France, ⁵INSERM 1098 RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Dijon, France, ⁶INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Dijon, France, ⁷Department of Pathology, Dijon-Bourgogne university Hospital, Dijon, France, ⁸Department of Pathology, Dijon University Hospital, Dijon, France, ⁹Department of Ophtalmology, Dijon-Bourgogne university Hospital, Dijon, France, ¹⁰Department of Ophthalmology, Dijon University Hospital, Dijon, France, ¹¹Department of Rheumatology , Dijon-Bourgogne University Hospital, Dijon, France, ¹²Department of Internal Medicine and Clinical Immunology, Dijon-Bourgogne University Hospital, Dijon, France
Background/Purpose: Polymyalgia rheumatica (PMR) is associated with giant cell arteritis (GCA) in 16 to 21% of cases. This raises the question of a pathophysiological continuum…
Abstract Number: 0719 • ACR Convergence 2023
Polymyalgia Rheumatica Following SarsCOV-2 Vaccination: A Single Center Cohort Study
Lindsay Lally¹, Aliza Bloostein¹, Deanna Jannat-Khan¹ and Robert Spiera², ¹Hospital for Special Surgery, New York, NY, ²Hosptial for Special Surgery, New York, NY
Background/Purpose: Polymyalgia rheumatica (PMR) incidence peaks in individuals between 70 and 80 years of age; this same group is also at increased risk of complications…
Abstract Number: 2393 • ACR Convergence 2023
CXCL9/IL-6 and MMP3/CD141 Ratio Allow to Discriminate Between Isolated PMR and GCA/PMR Overlap
andre ramon¹, helene Greigert², adrien guilloteau³, claudie cladière⁴, marion ciudad⁵, Sylvain Audia⁶, paul ornetti⁷, jean-Francis Maillefert⁷, Bernard Bonnotte² and Maxime Samson², ¹Department of Rheumatology, Dijon University Hospital, Dijon, France, ²Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ³Methodological Support Unit (USMR), Dijon-Bourgogne University Hospital, Dijon, France, ⁴INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Bourgogne Franche-Comté University, Dijon, France, ⁵INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Dijon, France, ⁶Department of Internal Medicine and Clinical Immunology, Dijon-Bourgogne University Hospital, Dijon, France, ⁷Department of Rheumatology , Dijon-Bourgogne University Hospital, Dijon, France
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are frequently overlapping conditions. It is estimated that 16 to 21% of PMR patients have GCA.…
Abstract Number: 1107 • ACR Convergence 2022
Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): A Prospective Study
Xinlei Ma, Fan Yang, Jin Lin and Weiqian Chen, Division of Rheumatology, the First Affiliated Hospital, Zhejiang University School of Medicine, HangZhou, China
Background/Purpose: Polymyalgia Rheumatica (PMR) is a common inflammatory disease in elderly persons whose pathogenesis is unclear. Glucocorticoids are the first-line drugs for patients with PMR,…
Abstract Number: 1543 • ACR Convergence 2022
Resolution of PMR Signs and Symptoms in Patients Treated with Sarilumab: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR) in Relapsing PMR
Robert Spiera¹, Sebastian Unizony², Kenneth J. Warrington³, Jennifer Sloane Lazar⁴, Angeliki Giannelou⁵, Michael C Nivens⁶, Bolanle Akinlade⁵, Wanling Wong⁴, Yong Lin⁴, Frank Buttgereit⁷, Valerie Devauchelle⁸, Andrea Rubbert-Roth⁹ and Bhaskar Dasgupta¹⁰, ¹Hospital for Special Surgery, New York, NY, ²Massachusetts General Hospital, Winchester, MA, ³Mayo Clinic, ROCHESTER, MN, ⁴Sanofi, Bridgewater, NJ, ⁵Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, NY, ⁷Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany, ⁸Université de Bretagne Occidentale, Brest, France, ⁹Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, ¹⁰Anglia Ruskin University, East Anglia, United Kingdom
Background/Purpose: Sarilumab, a human mAb against the IL-6 receptor α, has been approved in RA and is being investigated for PMR. The SAPHYR study (NCT03600818)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.